122 research outputs found
Bacteria-instructed B cells cross-prime naïve CD8+ T cells triggering effective cytotoxic responses.
In addition to triggering humoral responses, conventional B cells have been described in vitro to cross-present exogenous antigens activating naïve CD8+ T cells. Nevertheless, the way B cells capture these exogenous antigens and the physiological roles of B cell-mediated cross-presentation remain poorly explored. Here, we show that B cells capture bacteria by trans-phagocytosis from previously infected dendritic cells (DC) when they are in close contact. Bacterial encounter "instructs" the B cells to acquire antigen cross-presentation abilities, in a process that involves autophagy. Bacteria-instructed B cells, henceforth referred to as BacB cells, rapidly degrade phagocytosed bacteria, process bacterial antigens and cross-prime naïve CD8+ T cells which differentiate into specific cytotoxic cells that efficiently control bacterial infections. Moreover, a proof-of-concept experiment shows that BacB cells that have captured bacteria expressing tumor antigens could be useful as novel cellular immunotherapies against cancer.We are grateful to advanced light microscopy and cytometry facilities of CNB
for technical supporting. The research is supported by grants: SAF2017-84091-
R, and PID2020-116393RB-I00/AEI/10.13039/501100011033, financed by MCIN,
BFERO2020.04, financed by FERO foundation and PI20/0036 from ISCIII. RGF is
supported by BES-2016-076526 from the Spanish Ministry of Economy Industry and Competitiveness, JOP is supported by fellowship LCF/BQ/SO16/
52270012 from La Caixa, BHF is supported by FPU18/00895 and AMP by
FPU18/03199 from Ministry of Science, Innovation and Universities. LdC has
been supported by Juan de la Cierva grant IJC2018-035386-I and a contract
associated to SEV-2017-0712. EVC, AMP, AMAM, and NMM belong to the Spanish National Research Council (CSIC)’s Cancer Hub. Synopsis image made with
biorender.com by Eduardo Roman Camacho and Esteban Veiga. We thanks
Prof. Dan Portnoy who kindly provided bacterial strains.S
P53 in Penile Squamous Cell Carcinoma : A Pattern-Based Immunohistochemical Framework with Molecular Correlation
Penile squamous cell carcinomas harbouring mutations of TP53 have an increased risk of lymph node metastases and an impaired prognosis, but the mutational analysis of the TP53 gene is not available in many pathology laboratories. Although p53 immunohistochemistry (IHC) has been proposed as an alternative to the molecular analysis, the current method of evaluation of p53 IHC has many inaccuracies. The aim of our study was to determine, in a series of 40 penile tumours, if a recently described pattern-based framework of p53 IHC evaluation correlates better than the classical method with the TP53 mutational status. Our results show that the new method has a very good correlation with TP53 mutations (95% sensitivity; 92% specificity), higher than that of the classical method, and can be considered as a reliable surrogate of the TP53 mutational status. This new framework can help clinicians to better define risk groups and refine treatment strategies. p53 immunohistochemistry (IHC) has been proposed as a surrogate for TP53 mutations in penile squamous cell carcinomas (PSCC). We aimed to evaluate the performance of a pattern-based evaluation of p53 IHC in PSCC. Human papilloma virus (HPV) DNA testing, p16 and p53 IHC, and whole exome sequencing were performed in a series of 40 PSCC. p53 IHC was evaluated following a pattern-based framework and conventional p53 IHC evaluation. Out of 40 PSCC, 12 (30.0%) were HPV-associated, and 28 (70.0%) were HPV-independent. The agreement between the p53 IHC pattern-based evaluation and TP53 mutational status was almost perfect (k = 0.85). The sensitivity and accuracy of the pattern-based framework for identifying TP53 mutations were 95.5% and 92.5%, respectively, which were higher than the values of conventional p53 IHC interpretation (54.5% and 70.0%, respectively), whereas the specificity was the same (88.9%). In conclusions, the pattern-based framework improves the accuracy of detecting TP53 mutations in PSCC compared to the classical p53 IHC evaluation
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
PURPOSEIn the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in patients with platinum-sensitive, recurrent ovarian cancer who had a response to their last platinum-based chemotherapy. The objective of the study was to assess the clinical benefit and patient-reported outcomes in patients who had a partial response (PR) and complete response (CR) to their last platinum-based therapy.PATIENTS AND METHODSA total of 553 patients were enrolled in the trial. Of 203 patients with a germline BRCA mutation (gBRCAmut), 99 had a PR and 104 had a CR to their last platinum-based therapy; of 350 patients without a confirmed gBRCAmut (non?gBRCAmut), 173 had a PR and 177 had a CR. Post hoc analyses were carried out to evaluate safety and the risk of progression in these patients according to gBRCAmut status and response to their last platinum-based therapy. Ovarian cancer?specific symptoms and quality of life were assessed using the Functional Assessment of Cancer Therapy?Ovarian Symptom Index.RESULTSProgression-free survival was improved in patients treated with niraparib compared with placebo in both the gBRCAmut cohort (PR: hazard ratio [HR], 0.24; 95% CI, 0.131 to 0.441; P < .0001; CR: HR, 0.30; 95% CI, 0.160 to 0.546; P < .0001) and the non?gBRCAmut cohort (PR: HR, 0.35; 95% CI, 0.230 to 0.532; P < .0001; CR: HR, 0.58; 95% CI, 0.383 to 0.868; P = .0082). The incidence of any-grade and grade 3 or greater adverse events was manageable. No meaningful differences were observed between niraparib and placebo in PR and CR subgroups with respect to patient-reported outcomes.CONCLUSIONPatients achieved clinical benefit from maintenance treatment with niraparib regardless of response to the last platinum-based therapy
CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease
Autosomal dominant Alzheimer's disease (ADAD) offers a unique opportunity to study pathophysiological changes in a relatively young population with few comorbidities. A comprehensive investigation of proteome changes occurring in ADAD could provide valuable insights into AD-related biological mechanisms and uncover novel biomarkers and therapeutic targets. Furthermore, ADAD might serve as a model for sporadic AD, but in-depth proteome comparisons are lacking. We aimed to identify dysregulated CSF proteins in ADAD and determine the degree of overlap with sporadic AD. We measured 1472 proteins in CSF of PSEN1 or APP mutation carriers (n = 22) and age- and sex-matched controls (n = 20) from the Amsterdam Dementia Cohort using proximity extension-based immunoassays (PEA). We compared protein abundance between groups with two-sided t-tests and identified enriched biological pathways. Using the same protein panels in paired plasma samples, we investigated correlations between CSF proteins and their plasma counterparts. Finally, we compared our results with recently published PEA data from an international cohort of sporadic AD (n = 230) and non-AD dementias (n = 301). All statistical analyses were false discovery rate-corrected. We detected 66 differentially abundant CSF proteins (65 increased, 1 decreased) in ADAD compared to controls (q < 0.05). The most strongly upregulated proteins (fold change >1.8) were related to immunity (CHIT1, ITGB2, SMOC2), cytoskeletal structure (MAPT, NEFL) and tissue remodelling (TMSB10, MMP-10). Significant CSF-plasma correlations were found for the upregulated proteins SMOC2 and LILR1B. Of the 66 differentially expressed proteins, 36 had been measured previously in the sporadic dementias cohort, 34 of which (94%) were also significantly upregulated in sporadic AD, with a strong correlation between the fold changes of these proteins in both cohorts (rs = 0.730, P < 0.001). Twenty-nine of the 36 proteins (81%) were also upregulated among non-AD patients with suspected AD co-pathology. This CSF proteomics study demonstrates substantial biochemical similarities between ADAD and sporadic AD, suggesting involvement of the same biological processes. Besides known AD-related proteins, we identified several relatively novel proteins, such as TMSB10, MMP-10 and SMOC2, which have potential as novel biomarkers. With shared pathophysiological CSF changes, ADAD study findings might be translatable to sporadic AD, which could greatly expedite therapy development.</p
Discovery of novel CSF biomarkers to predict progression in dementia using machine learning
Providing an accurate prognosis for individual dementia patients remains a challenge since they greatly differ in rates of cognitive decline. In this study, we used machine learning techniques with the aim to identify cerebrospinal fluid (CSF) biomarkers that predict the rate of cognitive decline within dementia patients. First, longitudinal mini-mental state examination scores (MMSE) of 210 dementia patients were used to create fast and slow progression groups. Second, we trained random forest classifiers on CSF proteomic profiles and obtained a well-performing prediction model for the progression group (ROC-AUC = 0.82). As a third step, Shapley values and Gini feature importance measures were used to interpret the model performance and identify top biomarker candidates for predicting the rate of cognitive decline. Finally, we explored the potential for each of the 20 top candidates in internal sensitivity analyses. TNFRSF4 and TGF [Formula: see text]-1 emerged as the top markers, being lower in fast-progressing patients compared to slow-progressing patients. Proteins of which a low concentration was associated with fast progression were enriched for cell signalling and immune response pathways. None of our top markers stood out as strong individual predictors of subsequent cognitive decline. This could be explained by small effect sizes per protein and biological heterogeneity among dementia patients. Taken together, this study presents a novel progression biomarker identification framework and protein leads for personalised prediction of cognitive decline in dementia
Early-Career Coordinated Distributed Experiments: Empowerment Through Collaboration
Este artículo contiene 7 páginas, 1 tabla, 3 figuras.Coordinated distributed experiments (CDEs) enable the study of large-scale ecological
patterns in geographically dispersed areas, while simultaneously providing broad
academic and personal benefits for the participants. However, the effective involvement
of early-career researchers (ECRs) presents major challenges. Here, we analyze the
benefits and challenges of the first CDE exclusively led and conducted by ECRs (i.e.
ECR-CDE), which sets a baseline for similar CDEs, and we provide recommendations
for successful CDE execution. ECR-CDEs achieve most of the outcomes identified in
conventional CDEs as well as extensive benefits for the young cohort of researchers,
including: (i) receiving scientific credit, (ii) peer-training in new concepts and methods, (iii)
developing leadership and communication skills, (iv) promoting a peer network among
ECRs, and (v) building on individual engagement and independence. We also discuss
the challenges of ECR-CDEs, which are mainly derived from the lack of independence
and instability of the participants, and we suggest mechanisms to address them, such
as resource re-allocation and communication strategies. We conclude that ECR-CDEs
can be a relevant tool to empower ECRs across disciplines by fostering their training,
networking and personal well-being.The authors were supported by the following founding: NC
the support of the Beatriu de Pinós postdoctoral program of
the Government of Catalonia’s Secretariat for Universities and
Research of the Ministry of Economy and Knowledge (BP2016-
00215), EE by a predoctoral grant from the Basque Government
(2014-2017), AB by a Generalitat de Catalunya—Beatriu de
Pinós (BP-00385-2016), AMG-F by a predoctoral research grant
(BES-2013-065770) from the Spanish Ministry of Economy and
Competitiveness, MAr by a postdoctoral grant from the Basque
Government, MIA by a Juan de la Cierva postdoctoral grant
(FJCI-2015-26192), PR-L by a Margalida Comas postdoctoral
contract (PD/031/2018) funded by the Government of the
Balearic Islands and the European Social Fund, AP by a Ramón
Areces Foundation Postdoctoral Scholarship, and AL by a Kempe
Foundation stipend. DOMIPEX project was founded by the First
Call of Collaborative Projects among Young Researchers of the
Iberian Association of Limnology (AIL; 2013-2015).Peer reviewe
Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
SLE can affect any part of the gastrointestinal (GI) tract. GI symptoms are reported to occur in >50% of SLE patients. To describe the GI manifestations of SLE in the RELESSER (Registry of SLE Patients of the Spanish Society of Rheumatology) cohort and to determine whether these are associated with a more severe disease, damage accrual and a worse prognosis. METHODS: We conducted a nationwide, retrospective, multicentre, cross-sectional cohort study of 3658 SLE patients who fulfil =4 ACR-97 criteria. Data on demographics, disease characteristics, activity (SLEDAI-2K or BILAG), damage (SLICC/ACR/DI) and therapies were collected. Demographic and clinical characteristics were compared between lupus patients with and without GI damage to establish whether GI damage is associated with a more severe disease. RESULTS: From 3654 lupus patients, 3.7% developed GI damage. Patients in this group (group 1) were older, they had longer disease duration, and were more likely to have vasculitis, renal disease and serositis than patients without GI damage (group 2). Hospitalizations and mortality were significantly higher in group 1. Patients in group 1 had higher modified SDI (SLICC Damage Index). The presence of oral ulcers reduced the risk of developing damage in 33% of patients. CONCLUSION: Having GI damage is associated with a worse prognosis. Patients on a high dose of glucocorticoids are at higher risk of developing GI damage which reinforces the strategy of minimizing glucocorticoids. Oral ulcers appear to decrease the risk of GI damage. © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology
Complements alimentaris: control oficial
Complements alimentaris; Control oficial; Guia; Seguretat alimentàriaComplementos alimenticios; Control oficial ; Guia; Seguridad alimentariaFood supplements; Official controls; Guide; Food safetyAquesta publicació pretén donar una visió general del control oficial dels complements alimentaris a Catalunya mitjançant el recull de les diferents fonts normatives i documentals existents relatives als complements alimentaris, amb la finalitat principal de tenir una eina de suport al personal de l’Agència de Salut Pública de Catalunya, així com a altres administracions i professionals del sector.
A més, amb l’elaboració d’aquesta guia es vol ajudar a entendre què són els complements alimentaris i donar a conèixer què es fa des de les administracions públiques per mantenir la seguretat alimentària.
El document s’estructura en diversos apartats, que inclouen la inscripció al registre sanitari de les empreses que comercialitzen complements alimentaris, la notificació d’aquests complements i la normativa aplicable, sense deixar d’aprofundir en aspectes relacionats amb la composició, l’envasament, l’etiquetatge, els contaminants i els criteris microbiològics.
Aquesta guia inclou taules de consulta per identificar els ingredients que intervenen en la composició dels complements alimentaris i un protocol per a la revisió de l’etiquetatge correcte.
Índe
Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design
Introduction: We present the protocol of a large population-based case-control study of 5 common tumors
in Spain (MCC-Spain) that evaluates environmental exposures and genetic factors.
Methods: Between 2008-2013, 10,183 persons aged 20-85 years were enrolled in 23 hospitals and primary
care centres in 12 Spanish provinces including 1,115 cases of a new diagnosis of prostate cancer,
1,750 of breast cancer, 2,171 of colorectal cancer, 492 of gastro-oesophageal cancer, 554 cases of chronic
lymphocytic leukaemia (CLL) and 4,101 population-based controls matched by frequency to cases by age,
sex and region of residence. Participation rates ranged from 57% (stomach cancer) to 87% (CLL cases) and
from 30% to 77% in controls. Participants completed a face-to-face computerized interview on sociodemographic
factors, environmental exposures, occupation, medication, lifestyle, and personal and family
medical history. In addition, participants completed a self-administered food-frequency questionnaire
and telephone interviews. Blood samples were collected from 76% of participants while saliva samples
were collected in CLL cases and participants refusing blood extractions. Clinical information was recorded
for cases and paraffin blocks and/or fresh tumor samples are available in most collaborating hospitals.
Genotyping was done through an exome array enriched with genetic markers in specific pathways. Multiple
analyses are planned to assess the association of environmental, personal and genetic risk factors
for each tumor and to identify pleiotropic effects.
Discussion: This study, conducted within the Spanish Consortium for Biomedical Research in Epidemiology
& Public Health (CIBERESP), is a unique initiative to evaluate etiological factors for common cancers
and will promote cancer research and prevention in Spain.The study was partially funded by the “Accion Transversal
del Cancer”, approved on the Spanish Ministry Council on the
11th October 2007, by the Instituto de Salud Carlos III-FEDER
(PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286,
PS09/01903, PS09/02078, PS09/01662, PI11/01403, PI11/01889,
PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265,
PI12/01270, PI12/00715, PI12/00150), by the Fundación Marqués
de Valdecilla (API 10/09), by the ICGC International Cancer Genome
Consortium CLL, by the Junta de Castilla y León (LE22A10-2), by
the Consejería de Salud of the Junta de Andalucía (PI-0571), by the
Conselleria de Sanitat of the Generalitat Valenciana (AP 061/10),
by the Recercaixa (2010ACUP 00310), by the Regional Government
of the Basque Country by European Commission grants FOOD-CT-
2006-036224-HIWATE, by the Spanish Association Against Cancer
(AECC) Scientific Foundation, by the The Catalan Government
DURSI grant 2009SGR1489
Izaña Atmospheric Research Center. Activity Report 2015-2016
This report is a summary of the many activities at the Izaña Atmospheric Research Center to the broader community. The combination of operational activities, research and development in state-of-the-art measurement techniques, calibration and validation and international cooperation encompass the vision of WMO to provide world leadership in expertise and international cooperation in weather, climate, hydrology and related environmental issues
- …